Extracorporeal membrane oxygenation（ ECMO） is a technique that saves patients with severe heart and lung failure through long-term cardiopulmonary support. As an important risk factor for invasive fungal infection

the application of ECMO will also increase the mortality of patients with invasive fungal infection. Due to the extracorporeal circulation circuit

the pharmacokinetics（ PK）/pharmacodynamics（ PD） of antifungal drugs in ECMO patients have undergone major changes. This article summarizes the possible influencing factors of the PK/PD of drugs in ECMO patients

and introduces the characteristics of ECMO patients

the adjustment of antifungal treatment regimens and related population PK and physiological PK modeling studies

with the aim of providing reference for dosing application in similar patients. In the absence of prospective

multicenter

randomized controlled studies

therapeutic drug monitoring of antifungal drugs in ECMO patients is a more reasonable option.